E2F1-mediated GINS2 Transcriptional Activation Promotes Tumor Progression Through PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2022 May 9

PMID 35530279

Authors

Yao Zhang

Xiaopei Hao

Guoyong Han

Yiwei Lu

Zhiqiang Chen

Long Zhang

Jindao Wu

Xuehao Wang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) has high morbidity and mortality rates. It is therefore imperative to study the underlying mechanism of HCC to identify potential prognostic biomarkers and therapeutic targets. Recently, GINS2 has been identified to be a cancer-promoting gene in different cancer types. Nevertheless, the exact mechanism of GINS2 in HCC remains to be elucidated. To systematically explore the significance of GINS2, we first assessed the relative expression of GINS2 in pan-cancers based on data obtained from the HCCDB, TIMER, and TCGA databases. Then, we explored the clinical significance of GINS2 in HCC through Kaplan-Meier method as well as univariate and multivariate cox regression analysis. Additionally, functional enrichment analysis of GINS2 was done through GO, KEGG, PPI network, and immune cell infiltration analyses. Functional experiments were also conducted to investigate the biological significance of GINS2 in HCC cell lines. Our research revealed that GINS2 is involved in HCC progression and highlighted its potential value as a crucial diagnostic and therapeutic target for HCC.

Citing Articles

NCAPH Promotes the Proliferation of Prostate Cancer Cells Via Modulating the E2F1 Mediated PI3K/AKT/mTOR Axis.

Shi Q, Ma J, Pan X, Liu T, Chen K, Xu M Int J Med Sci. 2025; 22(4):940-954.

PMID: 39991770 PMC: 11843152. DOI: 10.7150/ijms.103444.

A dynamic co-expression approach reveals Gins2 as a potential upstream modulator of HNSCC metastasis.

Khayer N, Shabani S, Jalessi M, Joghataei M, Mahjoubi F Sci Rep. 2025; 15(1):3322.

PMID: 39865116 PMC: 11770085. DOI: 10.1038/s41598-024-82668-1.

GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas.

He H, Liang L, Jiang S, Liu Y, Huang J, Sun X Cell Death Dis. 2024; 15(3):205.

PMID: 38467631 PMC: 10928080. DOI: 10.1038/s41419-024-06586-w.

E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.

Liu Y, Chen P, Chen G, Chen X Ann Hematol. 2023; 102(12):3345-3355.

PMID: 37665348 DOI: 10.1007/s00277-023-05431-y.

Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.

Meng W, Jiang Z, Zhang X, Cai B, Ma L, Guan Y Comput Math Methods Med. 2022; 2022:3119721.

PMID: 36466552 PMC: 9711967. DOI: 10.1155/2022/3119721.

References

Gambus A, Jones R, Sanchez-Diaz A, Kanemaki M, van Deursen F, Edmondson R . GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat Cell Biol. 2006; 8(4):358-66. DOI: 10.1038/ncb1382. View

Liang J, Li H, Han J, Jiang J, Wang J, Li Y . Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway. Cell Death Dis. 2020; 11(8):614. PMC: 7427100. DOI: 10.1038/s41419-020-02858-3. View

Brouwer I, Lenstra T . Visualizing transcription: key to understanding gene expression dynamics. Curr Opin Chem Biol. 2019; 51:122-129. DOI: 10.1016/j.cbpa.2019.05.031. View

Bartha A, Gyorffy B . TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. Int J Mol Sci. 2021; 22(5). PMC: 7961455. DOI: 10.3390/ijms22052622. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Wu Y, Zhang Y, Qin X, Geng H, Zuo D, Zhao Q . PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma. Pharmacol Res. 2020; 160:105195. DOI: 10.1016/j.phrs.2020.105195. View

Xu F, Jin T, Zhu Y, Dai C . Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018; 37(1):110. PMC: 5975687. DOI: 10.1186/s13046-018-0777-4. View

Akamatsu N, Cillo U, Cucchetti A, Donadon M, Pinna A, Torzilli G . Surgery and Hepatocellular Carcinoma. Liver Cancer. 2016; 6(1):44-50. PMC: 5159722. DOI: 10.1159/000449344. View

Hao X, Zhang Y, Lu Y, Han G, Rong D, Sun G . STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway. iScience. 2021; 24(11):103223. PMC: 8551078. DOI: 10.1016/j.isci.2021.103223. View

10.

Zhang D, Liu J, Xie T, Jiang Q, Ding L, Zhu J . Oleate acid-stimulated HMMR expression by CEBPα is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma. Int J Biol Sci. 2020; 16(15):2812-2827. PMC: 7545721. DOI: 10.7150/ijbs.49785. View

11.

Carroni M, De March M, Medagli B, Krastanova I, Taylor I, Amenitsch H . New insights into the GINS complex explain the controversy between existing structural models. Sci Rep. 2017; 7:40188. PMC: 5223209. DOI: 10.1038/srep40188. View

12.

Prieto J, Melero I, Sangro B . Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12(12):681-700. DOI: 10.1038/nrgastro.2015.173. View

13.

Lian Y, Li S, Huang Y, Wei H, Chen D, Wang J . Up-regulated and interrelated expressions of GINS subunits predict poor prognosis in hepatocellular carcinoma. Biosci Rep. 2018; 38(6). PMC: 6435550. DOI: 10.1042/BSR20181178. View

14.

Huang L, Chen S, Fan H, Ji D, Chen C, Sheng W . GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK/MAPK signaling. Cancer Gene Ther. 2020; 28(7-8):839-849. PMC: 8370876. DOI: 10.1038/s41417-020-0206-7. View

15.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

16.

Zhang X, Zhong L, Liu B, Gao Y, Gao Y, Hu X . Effect of GINS2 on proliferation and apoptosis in leukemic cell line. Int J Med Sci. 2013; 10(12):1795-804. PMC: 3837239. DOI: 10.7150/ijms.7025. View

17.

Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A . Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci. 2015; 72(12):2337-47. PMC: 11113278. DOI: 10.1007/s00018-015-1867-5. View

18.

Lian Q, Wang S, Zhang G, Wang D, Luo G, Tang J . HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics Proteomics Bioinformatics. 2018; 16(4):269-275. PMC: 6205074. DOI: 10.1016/j.gpb.2018.07.003. View

19.

Pennacchio L, Bickmore W, Dean A, Nobrega M, Bejerano G . Enhancers: five essential questions. Nat Rev Genet. 2013; 14(4):288-95. PMC: 4445073. DOI: 10.1038/nrg3458. View

20.

Sun D, Zong Y, Cheng J, Li Z, Xing L, Yu J . GINS2 attenuates the development of lung cancer by inhibiting the STAT signaling pathway. J Cancer. 2021; 12(1):99-110. PMC: 7738824. DOI: 10.7150/jca.46744. View